Long-Term MINT Data Support Durable Response to Inebilizumab in Myasthenia Gravis

(MedPage Today) -- One-year results from the open-label extension of the phase III MINT trial presented at the American Association of Neuromuscular and Electrodiagnostic Medicine annual meeting showed that the benefits of inebilizumab (Uplizna...